Topical application of basic fibroblast growth factor reduces esophageal stricture and esophageal neural damage after sodium hydroxide-induced esophagitis in rats.
OBJECTIVE
To investigate the effect of topical application of basic fibroblast growth factor (bFGF) after caustic esophageal injury in rats.


METHODS
Thirty-six male rats were randomly divided into three groups. Corrosive esophageal injury was produced by internal application of 30% sodium hydroxide (NaOH) solution to the distal esophagus. Group A rats were uninjured. Group B rats were injured and untreated. Group C rats were injured and received topical bFGF (10 μg/ml). Surviving rats were killed at 28 days. The survival rate, body weight gain, symptoms and histopathological changes that included tissue damage score, ratio of esophageal luminal area/total esophageal area (LA/TA) and the proportion of a neural marker PGP 9.5-positive area were assessed.


RESULTS
The survival rate and the prevalence of symptoms were not significantly different between Groups B and C. Although the tissue damage score did not differ in Groups B and C, LA/TA was significantly higher in Group C than in Group B. The proportion of the PGP 9.5-positive area was significantly lower in Groups B and C than in Group A; however, it was higher in Group C than in Group B.


CONCLUSIONS
Topical application of bFGF was effective in preventing stricture after NaOH-induced esophagitis.
Division of Pediatric Surgery, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. yuichi.okata@gmail.com
Yuichi
Y
Okata
Chieko
C
Hisamatsu
Eiji
E
Nishijima
Yutaka
Y
Okita
D000287:Administration, Topical; D000818:Animals; D002423:Cause of Death; D004940:Esophageal Stenosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D004941:Esophagitis / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy; D004947:Esophagus / Q000187:drug effects / Q000294:innervation* / Q000473:pathology; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D015995:Prevalence; D011379:Prognosis; D051381:Rats; D017207:Rats, Sprague-Dawley; D012972:Sodium Hydroxide / Q000633:toxicity
D016222:Fibroblast Growth Factor 2; D012972:Sodium Hydroxide